{"id":{"repo_id":"cape-town","oai_identifier":"oai:open.uct.ac.za:11427/39803"},"canonical_url":"https://search.dev.ndltd.org/etd/cape-town/oai:open.uct.ac.za:11427/39803","repository":{"repo_id":"cape-town","name":"University of Cape Town","base_url":"https://open.uct.ac.za/oai/request"},"display":{"title":"A Retrospective Audit Of Biojet® Prostate Fusion Biopsies Amongst Patients Seen In A High-Volume Private Referral Centre In Cape Town Between January 2017 And April 2020","abstract":"Introduction: The field of prostate cancer has seen a dramatic change in its approach to diagnosis, from the advent of PSA in the 1980s to the transrectal ultrasound guided 12 core biopsies with a false negative rate of approximately 30%. Recent advances in this field involve fusing MRI images with real-time ultrasound images to guide the surgeon. The aim of the study was to evaluate the performance of Biojet® prostate fusion biopsy system in a high-volume private referral centre. Methods: Retrospective observational audit of men who presented to a private urology practice in Cape Town for Biojet® prostate fusion biopsy based on clinical suspicion for prostate cancer. Data were collected as per the recommendations of the Standards of Reporting for MRI-targeted Biopsy Studies (START) of the Prostate group and anonymously entered onto a Redcap database. Results: The median age of the patient population was 64 (SD 9.124) years. The median PSA level was 6.5 ng/ml (IQR- 4.7). Most patients (78/135) had a clinical stage of T1c (57%). In the biopsy naïve group, a total of 103 PIRADS lesions were identified. Amongst the PIRADS 3 lesions 15/28 lesions (53%) had a positive cancer diagnosis. Of the PIRADS 4 lesions 37/60 lesions (62%) had a positive cancer diagnosis and in the PIRADS 5 group 13/15 lesions (87%) had a positive cancer diagnosis. 21 of the 42 men (50%) with a previous negative prostate biopsy had a positive cancer diagnosis using the Biojet® prostate fusion biopsy. Conclusion: In this study the Biojet® prostate fusion biopsy performed similar to other international studies however the pickup rate of cancer in those who had a previous negative biopsy was higher than those seen in the other global studies.","abstract_html":"Introduction: The field of prostate cancer has seen a dramatic change in its approach to diagnosis, from the advent of PSA in the 1980s to the transrectal ultrasound guided 12 core biopsies with a false negative rate of approximately 30%. Recent advances in this field involve fusing MRI images with real-time ultrasound images to guide the surgeon. The aim of the study was to evaluate the performance of Biojet® prostate fusion biopsy system in a high-volume private referral centre. Methods: Retrospective observational audit of men who presented to a private urology practice in Cape Town for Biojet® prostate fusion biopsy based on clinical suspicion for prostate cancer. Data were collected as per the recommendations of the Standards of Reporting for MRI-targeted Biopsy Studies (START) of the Prostate group and anonymously entered onto a Redcap database. Results: The median age of the patient population was 64 (SD 9.124) years. The median PSA level was 6.5 ng/ml (IQR- 4.7). Most patients (78/135) had a clinical stage of T1c (57%). In the biopsy naïve group, a total of 103 PIRADS lesions were identified. Amongst the PIRADS 3 lesions 15/28 lesions (53%) had a positive cancer diagnosis. Of the PIRADS 4 lesions 37/60 lesions (62%) had a positive cancer diagnosis and in the PIRADS 5 group 13/15 lesions (87%) had a positive cancer diagnosis. 21 of the 42 men (50%) with a previous negative prostate biopsy had a positive cancer diagnosis using the Biojet® prostate fusion biopsy. Conclusion: In this study the Biojet® prostate fusion biopsy performed similar to other international studies however the pickup rate of cancer in those who had a previous negative biopsy was higher than those seen in the other global studies.","abstract_has_math":false,"creators":["Patel, Bhavinkumar"],"institution":"Division of General Surgery","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":["Kaestner, Lisa-Ann"],"committee_chairs":[],"committee_members":[],"year":2023,"date_issued":"2023","date_published":"2023","updated_at":"2026-07-22T22:23:02Z","subjects":["General Surgery"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/11427/39803","outbound_label":"Handle","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Kaestner, Lisa-Ann"]},{"key":"dc:creator","label":"Author","values":["Patel, Bhavinkumar"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2024-05-31T11:56:55Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2024-05-31T11:56:55Z"]},{"key":"dc:date.issued","label":"Date","values":["2023"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["Division of General Surgery"]},{"key":"dc:type","label":"Dc Type","values":["Thesis / Dissertation"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["Masters","MMed"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["General Surgery"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://hdl.handle.net/11427/39803"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Introduction: The field of prostate cancer has seen a dramatic change in its approach to diagnosis, from the advent of PSA in the 1980s to the transrectal ultrasound guided 12 core biopsies with a false negative rate of approximately 30%. Recent advances in this field involve fusing MRI images with real-time ultrasound images to guide the surgeon. The aim of the study was to evaluate the performance of Biojet® prostate fusion biopsy system in a high-volume private referral centre. Methods: Retrospective observational audit of men who presented to a private urology practice in Cape Town for Biojet® prostate fusion biopsy based on clinical suspicion for prostate cancer. Data were collected as per the recommendations of the Standards of Reporting for MRI-targeted Biopsy Studies (START) of the Prostate group and anonymously entered onto a Redcap database. Results: The median age of the patient population was 64 (SD 9.124) years. The median PSA level was 6.5 ng/ml (IQR- 4.7). Most patients (78/135) had a clinical stage of T1c (57%). In the biopsy naïve group, a total of 103 PIRADS lesions were identified. Amongst the PIRADS 3 lesions 15/28 lesions (53%) had a positive cancer diagnosis. Of the PIRADS 4 lesions 37/60 lesions (62%) had a positive cancer diagnosis and in the PIRADS 5 group 13/15 lesions (87%) had a positive cancer diagnosis. 21 of the 42 men (50%) with a previous negative prostate biopsy had a positive cancer diagnosis using the Biojet® prostate fusion biopsy. Conclusion: In this study the Biojet® prostate fusion biopsy performed similar to other international studies however the pickup rate of cancer in those who had a previous negative biopsy was higher than those seen in the other global studies."]},{"key":"dc:title","label":"Title","values":["A Retrospective Audit Of Biojet® Prostate Fusion Biopsies Amongst Patients Seen In A High-Volume Private Referral Centre In Cape Town Between January 2017 And April 2020"]}]}],"canonical_facts":{"dc:contributor.advisor":["Kaestner, Lisa-Ann"],"dc:creator":["Patel, Bhavinkumar"],"dc:date.accessioned":["2024-05-31T11:56:55Z"],"dc:date.available":["2024-05-31T11:56:55Z"],"dc:date.issued":["2023"],"dc:description.abstract":["Introduction: The field of prostate cancer has seen a dramatic change in its approach to diagnosis, from the advent of PSA in the 1980s to the transrectal ultrasound guided 12 core biopsies with a false negative rate of approximately 30%. Recent advances in this field involve fusing MRI images with real-time ultrasound images to guide the surgeon. The aim of the study was to evaluate the performance of Biojet® prostate fusion biopsy system in a high-volume private referral centre. Methods: Retrospective observational audit of men who presented to a private urology practice in Cape Town for Biojet® prostate fusion biopsy based on clinical suspicion for prostate cancer. Data were collected as per the recommendations of the Standards of Reporting for MRI-targeted Biopsy Studies (START) of the Prostate group and anonymously entered onto a Redcap database. Results: The median age of the patient population was 64 (SD 9.124) years. The median PSA level was 6.5 ng/ml (IQR- 4.7). Most patients (78/135) had a clinical stage of T1c (57%). In the biopsy naïve group, a total of 103 PIRADS lesions were identified. Amongst the PIRADS 3 lesions 15/28 lesions (53%) had a positive cancer diagnosis. Of the PIRADS 4 lesions 37/60 lesions (62%) had a positive cancer diagnosis and in the PIRADS 5 group 13/15 lesions (87%) had a positive cancer diagnosis. 21 of the 42 men (50%) with a previous negative prostate biopsy had a positive cancer diagnosis using the Biojet® prostate fusion biopsy. Conclusion: In this study the Biojet® prostate fusion biopsy performed similar to other international studies however the pickup rate of cancer in those who had a previous negative biopsy was higher than those seen in the other global studies."],"dc:identifier.uri":["http://hdl.handle.net/11427/39803"],"dc:publisher.department":["Division of General Surgery"],"dc:subject":["General Surgery"],"dc:title":["A Retrospective Audit Of Biojet® Prostate Fusion Biopsies Amongst Patients Seen In A High-Volume Private Referral Centre In Cape Town Between January 2017 And April 2020"],"dc:type":["Thesis / Dissertation"],"dc:type.qualificationlevel":["Masters","MMed"]},"updated_at":"2026-07-22T22:23:02Z"}